StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note published on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

TRACON Pharmaceuticals stock opened at $0.03 on Tuesday. The business has a 50 day simple moving average of $0.04 and a 200-day simple moving average of $0.28. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75. The stock has a market capitalization of $109,802.00, a PE ratio of 0.01 and a beta of 1.37.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.